NASDAQ:OCS - CH1242303498 - Common Stock
The current stock price of OCS is 16.145 USD. In the past month the price decreased by -7.31%. In the past year, price increased by 36.25%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 45.21 | 691.11B | ||
JNJ | JOHNSON & JOHNSON | 17.72 | 426.70B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 14.41 | 250.41B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 17.98 | 247.57B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 14.28 | 244.60B | ||
MRK | MERCK & CO. INC. | 10.9 | 209.71B | ||
PFE | PFIZER INC | 7.29 | 140.52B | ||
SNY | SANOFI-ADR | 11.2 | 121.05B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.98 | 95.68B | ||
GSK | GSK PLC-SPON ADR | 8.73 | 79.67B | ||
ZTS | ZOETIS INC | 25.08 | 69.13B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 49.88 | 47.26B |
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The company is headquartered in Zug, Zug and currently employs 49 full-time employees. The company went IPO on 2023-03-03. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
OCULIS HOLDING AG
Bahnhofstrasse 7
Zug ZUG CH
Employees: 49
Phone: 41588100182
The current stock price of OCS is 16.145 USD. The price decreased by -1.25% in the last trading session.
The exchange symbol of OCULIS HOLDING AG is OCS and it is listed on the Nasdaq exchange.
OCS stock is listed on the Nasdaq exchange.
12 analysts have analysed OCS and the average price target is 37.01 USD. This implies a price increase of 129.24% is expected in the next year compared to the current price of 16.145. Check the OCULIS HOLDING AG stock analysts ratings, price target forecast and up-and down grades for more detailed information.
OCULIS HOLDING AG (OCS) has a market capitalization of 840.51M USD. This makes OCS a Small Cap stock.
OCULIS HOLDING AG (OCS) currently has 49 employees.
OCULIS HOLDING AG (OCS) has a support level at 14.31 and a resistance level at 17.54. Check the full technical report for a detailed analysis of OCS support and resistance levels.
The Revenue of OCULIS HOLDING AG (OCS) is expected to decline by -19.84% in the next year. Check the estimates tab for more information on the OCS EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
OCS does not pay a dividend.
OCULIS HOLDING AG (OCS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.91).
The outstanding short interest for OCULIS HOLDING AG (OCS) is 0.02% of its float. Check the ownership tab for more information on the OCS short interest.
ChartMill assigns a technical rating of 1 / 10 to OCS. When comparing the yearly performance of all stocks, OCS turns out to be only a medium performer in the overall market: it outperformed 65.24% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to OCS. The financial health of OCS is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months OCS reported a non-GAAP Earnings per Share(EPS) of -2.91. The EPS decreased by -31.64% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -50.4% | ||
ROE | -63.27% | ||
Debt/Equity | 0 |
12 analysts have analysed OCS and the average price target is 37.01 USD. This implies a price increase of 129.24% is expected in the next year compared to the current price of 16.145.
For the next year, analysts expect an EPS growth of 5.71% and a revenue growth -19.84% for OCS